MCRB vs. GOSS, CAPR, PRQR, GLSI, SCPH, SKYE, PRLD, IVA, IXHL, and CRVO
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Gossamer Bio (GOSS), Capricor Therapeutics (CAPR), ProQR Therapeutics (PRQR), Greenwich LifeSciences (GLSI), scPharmaceuticals (SCPH), Skye Bioscience (SKYE), Prelude Therapeutics (PRLD), Inventiva (IVA), Incannex Healthcare (IXHL), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.
In the previous week, Gossamer Bio had 19 more articles in the media than Seres Therapeutics. MarketBeat recorded 23 mentions for Gossamer Bio and 4 mentions for Seres Therapeutics. Gossamer Bio's average media sentiment score of 0.41 beat Seres Therapeutics' score of 0.29 indicating that Gossamer Bio is being referred to more favorably in the news media.
Seres Therapeutics has higher revenue and earnings than Gossamer Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
Seres Therapeutics' return on equity of 0.00% beat Gossamer Bio's return on equity.
Seres Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 440.89%. Gossamer Bio has a consensus target price of $7.65, suggesting a potential upside of 947.95%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Seres Therapeutics.
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 5.1% of Seres Therapeutics shares are held by company insiders. Comparatively, 5.0% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Seres Therapeutics received 380 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 65.16% of users gave Gossamer Bio an outperform vote.
Summary
Seres Therapeutics beats Gossamer Bio on 10 of the 16 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
